Metro Drug
Concise Prescribing Info
Reduce incidence of infection in febrile neutropenia, non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated w/ significant incidence of severe neutropenia w/ fever. Reduction in time to neutrophil recovery & duration of fever, neutropenia & neutropenia-related clinical sequelae eg, febrile neutropenia, nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation. Mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis.
Dosage/Direction for Use
IV/SC Myelosuppressive chemotherapy Start at 5 mcg/kg/day as a single daily inj by SC bolus inj, by short IV infusion (15-30 min) or by continuous SC or IV infusion. Doses may be increased in increments of 5 mcg/kg for each chemotherapy cycle according to the duration and severity of the ANC nadir. Bone marrow transplant 10 mcg/kg/day given as an IV infusion of 4 or 24 hr, or as a continuous 24-hr SC infusion. Peripheral blood progenitor cell collection & therapy 10 mcg/kg/day SC either as a bolus or a continuous infusion for at least 4 days before the 1st leukapheresis procedure & continued until the last leukapheresis.
Hypersensitivity to E. coli-derived proteins or recombinant G-CSF.
Special Precautions
Allergic-type reactions eg, skin (rash, urticaria, facial edema), resp (wheezing, dyspnea) & CV (hypotension, tachycardia). Chronic myeloid leukemia (CML) & myelodysplasia. Monitor serious risk of splenic rupture. Do not use 24 hr before & after the administration of cytotoxic chemotherapy. Avoid radiation therapy. Perform CBC twice a wk to avoid the potential complications of excessive leukocytosis. Pregnancy & lactation.
Adverse Reactions
Sequelae of the underlying malignancy or cytotoxic chemotherapy malignancy or cytotoxic chemotherapy. Medullary bone pain. Nausea/vomiting, skeletal pain, alopecia, diarrhea, neutropenic fever, mucositis, fever, fatigue, anorexia, dyspnea, headache, cough, skin rash, chest pain, generalized weakness, sore throat stomatitis, constipation, pain (unspecified). Reversible elevations in uric acid, lactate dehydrogenase & alkaline phosphatase.
Drug Interactions
May potentiate the release of neutrophils w/ lithium.
ATC Classification
L03AA02 - filgrastim ; Belongs to the class of colony stimulating factors. Used as immunostimulants.
SciLocyte inj 300 mcg/mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in